| Similar Articles |
|---|
 |
Chemistry World
September 2007
Derek Lowe |
Column: In the Pipeline Will Phase Zero trials actually help drug development?   |
Chemistry World
August 27, 2015
Phillip Broadwith |
Drugs in a class of their own In the last month, three drugs in new therapeutic classes have been approved for cardiovascular diseases. |
Chemistry World
September 2009 |
Column: In the pipeline What's the most difficult therapeutic area for drug discovery? They're certainly not all created equal - or if they were, they have definitely diverged since then. The question can be narrowed down quite a bit. |
Chemistry World
January 2012 |
Column: In the pipeline Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
Pharmaceutical Executive
February 1, 2006
Ron Feemster |
Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets. |
Chemistry World
January 2007
Derek Lowe |
Opinion: In the Pipeline Here is a look at the recent failure of Pfizer's cholesterol drug, torcetrapib, and what it could mean for the future of pharmaceutical research. |
The Motley Fool
July 8, 2008
Brian Lawler |
Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards. |
Chemistry World
November 2009
Derek Lowe |
Column: In the pipeline The author advises opening your mind during the screening cascade taken by potential drug targets, and remaining goal orientated at all times |
Pharmaceutical Executive
September 1, 2005
Mattingly & Saxberg |
Biomarkers Come of Age In the past five years, biomarkers have become an essential part of pharmaceutical R&D. Seven industry experts explain how it happened - and what comes next. |
Chemistry World
June 23, 2015
Derek Lowe |
Missing the target There are enzymes that no mustard has ever cut, to steal a phrase from science fiction author James Blish. Phosphatases, the flip side of kinase activity, are a perfect example. |
Chemistry World
July 26, 2012
Derek Lowe |
Screen shots You might not think that the makeup of a compound screening collection could set off many arguments, but there are a few issues there that will do the trick almost every time. |
Bio-IT World
February 10, 2003
Malorye Branca |
Conquering Infinity with Chemical Genetics Harvard superchemist Stuart Schreiber defines the convergence of chemistry and biology. Now the field of chemical genetics is heading toward the clinic. |
Food Processing
March 2009
Diane Toops |
Kraft Foods Global Thinks Outside the Box with Bioactive Ingredients Kraft hires a pharmaceutical company to help it develop functional foods. |
Chemistry World
December 2008 |
Column: In the pipeline I've worked on two drug discovery efforts (one right after the other, as fate would have it) whose final compounds differed by essentially one methyl group from the starting points of each project. |
Chemistry World
January 7, 2014
Derek Lowe |
Is there a drug for that? One hears a lot about the concept of 'druggability' in pharmaceutical research. If that concept has any meaning (and it probably does), then the implication is that there must be such a thing as 'undruggability'. So what does that look like? |
Chemistry World
October 2008
Derek Lowe |
Column: In the pipeline The author seeks a cure for 'compound bloat' |
HHMI Bulletin
May 2011
Sarah C. P. Williams |
The Next Statin Although clinicians have firmly established the link between cholesterol levels and heart disease, there are still more questions than answers when it comes to the nitty-gritty molecular details of this connection. |
Chemistry World
May 2007
Derek Lowe |
In the Pipeline After months of bleak news about faltering pipelines and redundancies, it's time to find reasons to be cheerful about the drug industry. |
Bio-IT World
June 17, 2004
John Garvey |
Rational Decisions As companies in the computationally guided rational drug design sector mature, they should be more sure of the boundaries that surround their proprietary technologies. |
Pharmaceutical Executive
November 1, 2014
William Looney |
Pharma Science: It's Hard Amid a resurgence in drug development for hard-to-treat conditions, the bigger question is whether the times are as good for the industry tasked with rendering basic science into therapeutically effective medicines. |
Chemistry World
June 2008
Sarah Houlton |
Breaking the rules The author finds out about some chemical tricks that can give a new drug the best possible odds of success |
Pharmaceutical Executive
December 1, 2005
Ron Feemster |
The PharmExec 2005 Pipeline Report Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and -- at last -- innovative mechanisms for troublesome targets: Acomplia [rimonabant] by Sanofi-Aventis... AMG 162 [denosumab] by Amgen... etc. |
Chemistry World
May 31, 2009
Nina Notman |
The natural approach to winning at drug discovery High throughput drug screening is often described as a casino, with the odds stacked on the side of success as long as a big enough library is used. |
Reactive Reports
Issue 41
David Bradley |
Chip Chops Time off Drug Discovery Process A next-generation optical screening platform can screen a vast number of compounds rapidly by passing wave after wave of compounds in solution over the surface of the biochip. |
Chemistry World
September 2010 |
Column: In the pipeline Derek Lowe considers the quandaries of living in the age of the kinase |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
Chemistry World
August 2009
Derek Lowe |
Column: In the pipeline The author considers what makes a good looking drug molecule - and how beauty is in the eye of the beholder |
The Motley Fool
August 8, 2007
Brian Lawler |
Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline. |
Chemistry World
May 2008
Derek Lowe |
In the pipeline The controversy over cholesterol drug Vytorin has been going on for months. Surveying the wreckage, my first thought is: what a terrible shame the whole affair is. |
Chemistry World
January 2009
Derek Lowe |
Column: In the pipeline The author discusses the age-old tradition of passing the buck in drug development. |
The Motley Fool
June 29, 2011
Brian Orelli |
Doubling Up in Biotech Lilly hits multiple targets with one drug. |
Chemistry World
March 26, 2014
Phillip Broadwith |
AstraZeneca boosts open innovation efforts Astrazeneca has launched a new web portal, bringing together new and existing open innovation programs. The aim is to make collaboration with academics, other companies, governments and non-government organizations easier. |
Chemistry World
June 2009
Derek Lowe |
Column: In the pipeline The author wonders about pharmaceutical companies' motives for collaboration |
